公开(公告)号：US20200216552A1

公开(公告)日：2020-07-09

申请号：US16795823

申请日：2020-02-20

Applicant: Bristol-Myers Squibb Company

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Lixin Lang ,  Urvi Aras ,  Diane Shevell ,  Christine Kratt ,  Karen Price ,  Suzanne Suchard

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

公开(公告)号：US11466091B2

公开(公告)日：2022-10-11

申请号：US16795823

申请日：2020-02-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Lixin Lang ,  Urvi Aras ,  Diane Shevell ,  Christine Kratt ,  Karen Price ,  Suzanne Suchard

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

公开(公告)号：US11136406B2

公开(公告)日：2021-10-05

申请号：US16723047

申请日：2019-12-20

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Anish Suri ,  Steven Sheriff ,  Suzanne Suchard ,  Aaron Yamniuk ,  Stanley Krystek ,  James Tamura ,  James Bryson ,  Steven Grant ,  Philip Drew

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/18 ,  A61K39/00

Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

公开(公告)号：US10544228B2

公开(公告)日：2020-01-28

申请号：US15259828

申请日：2016-09-08

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Anish Suri ,  Steven Sheriff ,  Suzanne Suchard ,  Aaron Yamniuk ,  Stanley Krystek ,  James Tamura ,  James Bryson ,  Steven Grant ,  Philip Drew

IPC: C12N15/13 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/18 ,  A61K39/00

Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).